Featured Research

from universities, journals, and other organizations

Promising breakthrough for transplant patients

Date:
February 27, 2013
Source:
Centre hospitalier de l'Université de Montréal
Summary:
Scientists have discovered a new cause of organ rejection in some kidney transplant patients. They have identified a new class of antibodies -- anti-LG3 -- which, when activated, led to severe rejection episodes associated with a high rate of organ loss. This discovery, which holds promise for organ recipients.

A team led by Dr. Marie-Josée Hébert from the University of Montreal Hospital Research Centre (CRCHUM) has discovered a new cause of organ rejection in some kidney transplant patients. Her team has identified a new class of antibodies -- anti-LG3 -- which when activated lead to severe rejection episodes associated with a high rate of organ loss.

This discovery, which holds promise for organ recipients, was published in the online version of the American Journal of Transplantation.

Rejection is one of the major obstacles to organ transplantation. For the most part, it occurs when the recipient's immune system recognizes the transplanted organ as a foreign body that must be eliminated. However, even when there is a good donor-recipient immunologic match, the recipient's immune system can attack the transplanted organ's blood vessels. Called acute vascular rejection, this phenomenon often leads to a high rate of graft loss.

Hébert's team has characterized anti-LG3, an antibody that some patients produce to attack LG3, a protein that plays an important role in vascular repair and regeneration. "In these patients, the secretion of LG3 by the new kidney stimulates the activity of these antibodies which attack and injure the blood vessels of the transplanted organ. The net effect is that the normal healing process of the transplanted organ is hindered, if not interrupted, leading to impaired kidney function and even loss," explains Dr. Hébert.

By identifying the heightened presence of anti-LG3 antibodies in patients prior to transplantation, researchers will be able to predict the development of severe rejection episodes. "These results are quite exciting," notes Hébert, "and suggest that new therapies aimed at eliminating LG3 antibodies prior to transplantation could reduce organ rejection or limit its severity."

Given that LG3 is present in all blood vessels and thus in all transplanted organs, Hébert's results could also explain rejection of other types of transplanted organ, such as the heart, lung and pancreas.


Story Source:

The above story is based on materials provided by Centre hospitalier de l'Université de Montréal. Note: Materials may be edited for content and length.


Journal Reference:

  1. H. Cardinal, M. Dieudé, N. Brassard, S. Qi, N. Patey, M. Soulez, D. Beillevaire, F. Etcheverry, C. Daniel, Y. Durocher, F. Madore, M. J. Hébert. Antiperlecan Antibodies Are Novel Accelerators of Immune-Mediated Vascular Injury. American Journal of Transplantation, 2013; DOI: 10.1111/ajt.12168

Cite This Page:

Centre hospitalier de l'Université de Montréal. "Promising breakthrough for transplant patients." ScienceDaily. ScienceDaily, 27 February 2013. <www.sciencedaily.com/releases/2013/02/130227113102.htm>.
Centre hospitalier de l'Université de Montréal. (2013, February 27). Promising breakthrough for transplant patients. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/2013/02/130227113102.htm
Centre hospitalier de l'Université de Montréal. "Promising breakthrough for transplant patients." ScienceDaily. www.sciencedaily.com/releases/2013/02/130227113102.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) — A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) — Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) — California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
New Drug Could Reduce Cardiovascular Deaths

New Drug Could Reduce Cardiovascular Deaths

Newsy (Aug. 30, 2014) — The new drug from Novartis could reduce cardiovascular deaths by 20 percent compared to other similar drugs. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins